International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company(GEMA.ME)
No price history available.
Key financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | RUBm | 243 | 266 | 255 | 284 | 349 | 377 | N/A | N/A |
| Operating profit | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | RUBm | 123 | 129 | 98 | 126 | 151 | 158 | N/A | N/A |
| EPS reported | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
The International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company offers authorized private biobanking services, enabling individuals to store their cord blood stem cells and umbilical cord tissue. Its operations extend across Russia and the Commonwealth of Independent States. Established in 2003, this entity is headquartered in Moscow, Russia, and operates as an affiliate of Human Stem Cells Institute PJSC.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company (GEMA.ME)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
The International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company offers authorized private biobanking services, enabling individuals to store their cord blood stem cells and umbilical cord tissue. Its operations extend across Russia and the Commonwealth of Independent States. Established in 2003, this entity is headquartered in Moscow, Russia, and operates as an affiliate of Human Stem Cells Institute PJSC.